Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Roche Pulls Ahead in Oncology, Expected to Remain Market Leader Until 2023

By GBI Research | June 27, 2017

Roche will remain oncology market leader to 2023, in an increasingly fragmented but growing therapy area, says GBI Research.

None of the products due to enter the oncology market by 2023 are expected to reach the same levels of success as the highest revenue-generating drugs currently in the market—such as Revlimid, Opdivo, and Avastin—according to business intelligence provider GBI Research.

The company’s latest report states that the oncology landscape is now highly competitive, with entrenched products competing for market share even in the second-line segment of most indications. This means that the uptake of new products requires time, entailing a market share ramp-up period in excess of 10 years in some instances. In addition, the continuing trend towards treating targeted patient subsets means that the available market shares for newer drugs are more constrained.

However, there are a number of late-stage pipeline candidates that are expected to generate strong annual revenue during the forecast period, with the PD-1 inhibitor durvalumab and the CDK-4 and -6 inhibitor abemaciclib expected to achieve blockbuster revenues by 2023, according to GBI Research.

Newer CAR-T cell therapies Tisagenlecleucel-T and KTE-C19 are also expected to make an entry into the market and achieve blockbuster revenues during this period. Moreover, the exceptionally large overall pipeline, which consists of 7,701 products, points to continued long-term growth in the oncology market.

Dominic Trewartha, Managing Analyst for GBI Research, explains: “The key market players, namely Roche, Celgene, Bristol-Myers Squibb and Novartis, are forecast to achieve strong revenue growth throughout the market period, although the entry and growth of new players such as AstraZeneca, Pfizer and Merck means that their overall market shares are expected to decline.

“The oncology market shares of Roche, Celgene, Bristol-Myers Squibb, and Novartis are all anticipated to decrease substantially by 2023. Nevertheless, despite the approaching patent expiries of Roche’s Avastin, Kadcycla, Perjeta, and Tarceva, the company is expected to maintain the highest market share of any company, accounting for 25% of revenues in the oncology market, excluding generics, by 2023 – down from 45% in 2016.”

(Source: GBI Research)

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE